Demonstrated strong safety and favorable pharmacokinetics in Phase 1 study A First-in-class oral small molecule modulating immune cell metabolism via glycogen phosphorylase inhibition Once-daily oral ...
Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase 3, multicenter, randomized, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback